Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease.
Parkinson's disease leads to major disability that impairs the quality of life of patients and leads to increased health-care costs. While there is no proven neuroprotective treatment, more basic-science research and clinical trials are needed to identify drugs that slow or halt the progression of the disorder. The mainstay of symptomatic treatment is levodopa. With long-term use, levodopa causes motor complications including involuntary movements and response fluctuations. These have lead to more cautious prescribing of levodopa. Dopamine agonists can be used as an alternative initial therapy to delay the onset of motor complications but at the expense of more dopaminergic adverse events, poorer control of motor symptoms, and increased cost. Once motor complications have developed, adjuvant therapy with dopamine agonists or entacapone can reduce off time and levodopa dose. Severe fluctuations that are not controlled by oral combination therapy can be controlled with subcutaneous apomorphine injections or infusions.
Clarke
Carl E
CE
University of Birmingham, UK. c.e.clarke@bham.ac.uk
D000465:Algorithms; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D016472:Motor Neuron Disease / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications / Q000473:pathology / Q000517:prevention & control*
D000978:Antiparkinson Agents; D018696:Neuroprotective Agents; D004298:Dopamine